Tissue retention of doxorubicin and its effects on cardiac, smooth, and skeletal muscle function

Reid Hayward, David Hydock, Noah Gibson, Stephanie Greufe, Eric Bredahl, Traci Parry

Research output: Contribution to journalArticle

39 Citations (Scopus)

Abstract

Cancer-related fatigue is a pervasive syndrome experienced by a majority of cancer patients undergoing treatment, and muscular dysfunction may be a key component in the development and progression of this syndrome. Doxorubicin (DOX) is a commonly used antineoplastic agent used in the treatment of many cancers. The purpose of this study was to determine the effect of DOX exposure on the function of cardiac, skeletal, and smooth muscle tissues and examine the role accumulation of DOX may play in this process. In these studies, rats were treated with DOX and measurements of cardiac, skeletal, and smooth muscle function were assessed 1, 3, and 5 days after exposure. All muscular tissues showed significant and severe dysfunction, yet there was heterogeneity both in the time course of dysfunction and in the accumulation of DOX. Cardiac and skeletal muscle exhibited a time-dependent progressive decline in function during the 5 days following DOX treatment. In contrast, vascular function showed a decline in function that could be characterized as rapid onset and was sustained for the duration of the 5-day observation period. DOX accumulation was greatest in cardiac tissue, yet all muscular tissues showed a similar degree of dysfunction. Our data suggest that in muscular tissues both DOX-dependent and DOX-independent mechanisms may be involved with the muscular dysfunction observed following DOX treatment. Furthermore, this study highlights the fact that dysfunction of skeletal and smooth muscle may be an underappreciated aspect of DOX toxicity and may be a key component of cancer-related fatigue in these patients.

Original languageEnglish
Pages (from-to)177-187
Number of pages11
JournalJournal of Physiology and Biochemistry
Volume69
Issue number2
DOIs
StatePublished - Jun 2013
Externally publishedYes

Fingerprint

Doxorubicin
Smooth Muscle
Muscle
Myocardium
Skeletal Muscle
Tissue
Fatigue
Neoplasms
Fatigue of materials
Patient treatment
Therapeutics
Antineoplastic Agents
Blood Vessels
Toxicity
Rats
Observation
Muscles

All Science Journal Classification (ASJC) codes

  • Physiology
  • Biochemistry

Cite this

Tissue retention of doxorubicin and its effects on cardiac, smooth, and skeletal muscle function. / Hayward, Reid; Hydock, David; Gibson, Noah; Greufe, Stephanie; Bredahl, Eric; Parry, Traci.

In: Journal of Physiology and Biochemistry, Vol. 69, No. 2, 06.2013, p. 177-187.

Research output: Contribution to journalArticle

Hayward, Reid ; Hydock, David ; Gibson, Noah ; Greufe, Stephanie ; Bredahl, Eric ; Parry, Traci. / Tissue retention of doxorubicin and its effects on cardiac, smooth, and skeletal muscle function. In: Journal of Physiology and Biochemistry. 2013 ; Vol. 69, No. 2. pp. 177-187.
@article{ca1ebd97e3894b0fb01009abfe2d891d,
title = "Tissue retention of doxorubicin and its effects on cardiac, smooth, and skeletal muscle function",
abstract = "Cancer-related fatigue is a pervasive syndrome experienced by a majority of cancer patients undergoing treatment, and muscular dysfunction may be a key component in the development and progression of this syndrome. Doxorubicin (DOX) is a commonly used antineoplastic agent used in the treatment of many cancers. The purpose of this study was to determine the effect of DOX exposure on the function of cardiac, skeletal, and smooth muscle tissues and examine the role accumulation of DOX may play in this process. In these studies, rats were treated with DOX and measurements of cardiac, skeletal, and smooth muscle function were assessed 1, 3, and 5 days after exposure. All muscular tissues showed significant and severe dysfunction, yet there was heterogeneity both in the time course of dysfunction and in the accumulation of DOX. Cardiac and skeletal muscle exhibited a time-dependent progressive decline in function during the 5 days following DOX treatment. In contrast, vascular function showed a decline in function that could be characterized as rapid onset and was sustained for the duration of the 5-day observation period. DOX accumulation was greatest in cardiac tissue, yet all muscular tissues showed a similar degree of dysfunction. Our data suggest that in muscular tissues both DOX-dependent and DOX-independent mechanisms may be involved with the muscular dysfunction observed following DOX treatment. Furthermore, this study highlights the fact that dysfunction of skeletal and smooth muscle may be an underappreciated aspect of DOX toxicity and may be a key component of cancer-related fatigue in these patients.",
author = "Reid Hayward and David Hydock and Noah Gibson and Stephanie Greufe and Eric Bredahl and Traci Parry",
year = "2013",
month = "6",
doi = "10.1007/s13105-012-0200-0",
language = "English",
volume = "69",
pages = "177--187",
journal = "Journal of Physiology and Biochemistry",
issn = "1138-7548",
publisher = "Springer Netherlands",
number = "2",

}

TY - JOUR

T1 - Tissue retention of doxorubicin and its effects on cardiac, smooth, and skeletal muscle function

AU - Hayward, Reid

AU - Hydock, David

AU - Gibson, Noah

AU - Greufe, Stephanie

AU - Bredahl, Eric

AU - Parry, Traci

PY - 2013/6

Y1 - 2013/6

N2 - Cancer-related fatigue is a pervasive syndrome experienced by a majority of cancer patients undergoing treatment, and muscular dysfunction may be a key component in the development and progression of this syndrome. Doxorubicin (DOX) is a commonly used antineoplastic agent used in the treatment of many cancers. The purpose of this study was to determine the effect of DOX exposure on the function of cardiac, skeletal, and smooth muscle tissues and examine the role accumulation of DOX may play in this process. In these studies, rats were treated with DOX and measurements of cardiac, skeletal, and smooth muscle function were assessed 1, 3, and 5 days after exposure. All muscular tissues showed significant and severe dysfunction, yet there was heterogeneity both in the time course of dysfunction and in the accumulation of DOX. Cardiac and skeletal muscle exhibited a time-dependent progressive decline in function during the 5 days following DOX treatment. In contrast, vascular function showed a decline in function that could be characterized as rapid onset and was sustained for the duration of the 5-day observation period. DOX accumulation was greatest in cardiac tissue, yet all muscular tissues showed a similar degree of dysfunction. Our data suggest that in muscular tissues both DOX-dependent and DOX-independent mechanisms may be involved with the muscular dysfunction observed following DOX treatment. Furthermore, this study highlights the fact that dysfunction of skeletal and smooth muscle may be an underappreciated aspect of DOX toxicity and may be a key component of cancer-related fatigue in these patients.

AB - Cancer-related fatigue is a pervasive syndrome experienced by a majority of cancer patients undergoing treatment, and muscular dysfunction may be a key component in the development and progression of this syndrome. Doxorubicin (DOX) is a commonly used antineoplastic agent used in the treatment of many cancers. The purpose of this study was to determine the effect of DOX exposure on the function of cardiac, skeletal, and smooth muscle tissues and examine the role accumulation of DOX may play in this process. In these studies, rats were treated with DOX and measurements of cardiac, skeletal, and smooth muscle function were assessed 1, 3, and 5 days after exposure. All muscular tissues showed significant and severe dysfunction, yet there was heterogeneity both in the time course of dysfunction and in the accumulation of DOX. Cardiac and skeletal muscle exhibited a time-dependent progressive decline in function during the 5 days following DOX treatment. In contrast, vascular function showed a decline in function that could be characterized as rapid onset and was sustained for the duration of the 5-day observation period. DOX accumulation was greatest in cardiac tissue, yet all muscular tissues showed a similar degree of dysfunction. Our data suggest that in muscular tissues both DOX-dependent and DOX-independent mechanisms may be involved with the muscular dysfunction observed following DOX treatment. Furthermore, this study highlights the fact that dysfunction of skeletal and smooth muscle may be an underappreciated aspect of DOX toxicity and may be a key component of cancer-related fatigue in these patients.

UR - http://www.scopus.com/inward/record.url?scp=84879418973&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84879418973&partnerID=8YFLogxK

U2 - 10.1007/s13105-012-0200-0

DO - 10.1007/s13105-012-0200-0

M3 - Article

C2 - 22890792

AN - SCOPUS:84879418973

VL - 69

SP - 177

EP - 187

JO - Journal of Physiology and Biochemistry

JF - Journal of Physiology and Biochemistry

SN - 1138-7548

IS - 2

ER -